BusinessAbeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business HighlightsBy Nasdaq OMXMar 16, 2018, 9:10 PM UTC
BusinessAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis BullosaBy Nasdaq OMXJan 29, 2018, 1:45 PM UTC
BusinessAbeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXNov 15, 2017, 1:25 PM UTC
BusinessAbeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, OhioBy Nasdaq OMXOct 4, 2017, 12:45 PM UTC
BusinessAbeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis BullosaBy Nasdaq OMXAug 29, 2017, 1:05 PM UTC
BusinessAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017By Nasdaq OMXAug 17, 2017, 1:15 PM UTC
BusinessAbeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis BullosaBy Nasdaq OMXJul 18, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 30, 2017, 12:32 PM UTC
